Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040975 | 0.80 | CRBN (0.59) | DDB1CRBN | |
| SCHEMBL23139814 | 0.76 | CRBN (0.61) | DDB1CRBNKMT2AMEN1ALDH1A1 | |
| SCHEMBL31040960 | 0.75 | DDB1 (0.65) | DDB1CRBNKMT2AMEN1RAB9A | |
| SCHEMBL31040954 | 0.75 | DDB1 (0.54) | DDB1CRBNKMT2AMEN1ALDH1A1 | |
| SCHEMBL29321374 | 0.72 | CRBN (0.60) | DDB1CRBNKMT2AMEN1 | |
| SCHEMBL31040959 | 0.72 | DDB1 (0.73) | DDB1CRBN | |
| SCHEMBL31040971 | 0.72 | DDB1 (0.54) | DDB1CRBN | |
| SCHEMBL31040963 | 0.72 | CRBN (0.63) | DDB1CRBNKDM4EALDH1A1 | |
| SCHEMBL30874149 | 0.72 | ACACB (0.45) | DDB1CRBNKMT2AMEN1 | |
| SCHEMBL25122532 | 0.71 | CRBN (0.67) | DDB1CRBNKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRBN, CUL1, CUL5 | DDB1 188/4885CRBN 1/4885CSF1R 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.